This advertorial has been commissioned and developed by GSK

GSK logo
Avamys product logo
Avamys_27.5_micrograms_spray

Avamys nasal spray

Avamys nasal spray is indicated for the treatment of the symptoms of allergic rhinitis (AR) in adults, adolescents and children (aged six and over).1

Learn more

Meet your Avamys patients

Young boy eating breakfast

Meet Oliver

  • 8-year-old schoolboy
  • Has had to miss school and cannot go outside, missing his sports day
  • On an oral antihistamine but his symptoms remained uncontrolled

How can Avamys help?

Young woman listening to music

Meet Anna

  • 32-year-old graphic designer
  • Currently using another nasal spray (OTC/Rx)
  • Experienced drip down of the nasal spray to the throat
  • Impacted her work and she was unable to cope with severity of her symptoms

How can Avamys help?


How to use the Avamys device

Watch the video to find out more.

In a patient preference study, the Avamys device was preferred by more patients than the Nasonex device*2

Overall, significantly more patients preferred FFNS over MFNS, p<0.0012

GSK FFNS GSK MFNS

Overall, 5 patients (2%) reported AEs with FFNS and 13 patients (4%) with MFNS. Few common AEs were reported: rhinorrhoea, nasal discomfort, cough. No severe safety issues were identified during the study.2

GSK Management of allergic rhinitis icon

Management of AR

AR—role of sensory attributes in management of AR.

Watch the video

GSK Avamys dosage and device icon

A patient-friendly, easy-to-use device

Avamys is delivered via a patient-friendly, easy-to-use device.3,4,5

Read more

GSK targeted action with Avamys icon

Receptor affinity - Avamys

Find out about tissue retention and receptor affinity of fluticasone propionate.

Learn more

GSK Avamys guideline recommendations icon

Guideline recommendations

INCS is recommended by various guidelines for AR.6–10

Find out more


*Multicentre, randomised, double-blind, cross-over study where patient (n=300) preferences were determined by using three questionnaires (Overall Preference, Immediate Attributes and Delayed Attributes).

AE=adverse event; AR=allergic rhinitis; FFNS=fluticasone furoate nasal spray; INCS=intranasal corticosteroids; MFNS=mometasone furoate nasal spray; OTC=over the counter; Rx=medical prescription


  1. GlaxoSmithKline UK. AVAMYS 27.5 micrograms/spray, nasal spray suspensionsummary of product characteristicswww.medicines.org.uk/emc/product/6439
  2. Yanez A, Dimitroff A, Bremner P, et al. A patient preference study that evaluated fluticasone furoate and mometasone furoate nasal sprays for allergic rhinitis. Allergy Rhinol. 2016; 7 (4): e183–e192.
  3. Berger WE, Godfrey JW, Slater AL. Intranasal corticosteroids: the development of a drug delivery device for fluticasone furoate as a potential step toward improved compliance. Expert Opin Drug Deliv. 2007; 4 (6): 89–701.
  4. Berger WE, Godfrey JW, Grant AC, et al. Fluticasone furoate (FF) nasal spray: development of a next-generation delivery system for allergic rhinitis [abstract no. 907]. J Allergy Clin Immunol. 2007; 119: S231.
  5. Godfrey JW, Grant AC, Slater AL. Fluticasone Furoate (FF) Nasal spray-ergonomic considerations for a next generation delivery system. J Allergy Clin lmmunol. 2007; 119 (Suppl. 1): S230.
  6. Brozek J, Bousquet J, Agache I, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017; 140 (4): 950–958.
  7. Seidman M, Gurgel RK, Lin SY, et al. Clinical Practice Guideline: Allergic Rhinitis. Otolaryngol Head Neck Surg. 2015: 152 (18) S1–S43.
  8. Scadding GK, Kariyawasam HH, Scadding G, et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis. Clin Exp Allergy. 2017; 47: 856–889.
  9. Wallace DV, Dykewicz MS, Oppenheimer J, et al. Pharmacologic Treatment of Seasonal Allergic Rhinitis: Synopsis of Guidance from the 2017 Joint Task Force on Practice Parameters. Ann Intern Med. 2017; 167  (12): 876–881.
  10. Santos A, Borrego LM, Rotiroti G, et al. The need for patient-focused therapy for children and teenagers with allergic rhinitis: a case-based review of current European practice. Clin Transl Allergy. 2015; 5: 2.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441

Avamys is a registered trademark of the GlaxoSmithKline group of companies

PM-GB-FLF-WCNT-190001

Date of preparation: October 2019